Petri Bio
Petri Bio is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Petri Bio.
Petri Bio is a company.
Key people at Petri Bio.
Key people at Petri Bio.
Petri Bio is a biotechnology company founded in 2019 that develops novel therapeutics and health products by training and engineering microbes, particularly gut microbes, to enhance human healthspan and lifespan.[1][3][4] It leverages microorganisms to screen for useful compounds in microbial genomes and optimize them for disease treatment, using advanced techniques like systems biology and fuzzy logic for more accurate, natural products than traditional methods.[3][4] The company serves the healthcare and longevity sectors, solving problems in intercellular communication and disease treatment through peptides and small molecule drugs, while operating at a pre-seed stage with $260K raised.[1][4] Petri Bio also functions as a funding platform for formation-stage bioengineering startups at the biology-engineering intersection, co-founded by leaders from Ginkgo Bioworks, Beyond Meat, Twist Biosciences, and others like Stan Lapidus of Exact Sciences.[2][3]
Petri Bio emerged in 2019 from visionary bio-entrepreneurs addressing gaps in microbial applications for health and sustainability.[1][2] Co-founders include Shu Li and Joe Schinaman, alongside iconic figures like Stan Lapidus (Chairman & CEO of Exact Sciences and Petri co-founder), and leaders behind Ginkgo Bioworks, Beyond Meat, and Twist Biosciences.[2][3][4] Based initially in Torrance, California (370 Amapola Ave Suite 100), with ties to Boston, Massachusetts, the company arose from recognizing microbes' untapped potential in therapeutics and bioengineering.[1][4] Early focus blended company development with startup funding, supporting pivots like lab spaces from shipping containers and remote team-building during challenges, while investing in areas like food, agriculture, biomaterials, and carbon removal.[2]
Petri Bio rides the microbiome and synthetic biology wave, capitalizing on trends in engineered microbes for therapeutics, sustainability, and longevity amid rising demand for precise, biology-based solutions to health and environmental challenges.[1][2][4] Timing aligns with post-2020 biotech surges in remote innovation and pivots (e.g., container labs, Zoom fundraising), fueled by market forces like aging populations, climate-driven biomaterial needs, and advances in genome screening.[2] It influences the ecosystem by funding stealth startups in protein engineering, soil carbon measurement, and wound sensors, fostering perseverance in bioengineering while democratizing access to microbial tech for drug discovery and materials.[2]
Petri Bio's hybrid model positions it to scale microbial therapeutics and fund the next bioengineering wave, potentially expanding into personalized medicine and sustainable materials as AI-bio convergence accelerates.[2][4] Trends like rapid genome optimization and microbiome modulation will shape its path, with influence growing through portfolio successes in stealth protein engineering and carbon tech.[2] As pre-seed momentum builds from its $260K raise, expect partnerships with longevity leaders to propel healthspan innovations, reinforcing its role from microbial training pioneer to ecosystem catalyst.[1][4]
